Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Maria L. Yataco"'
Publikováno v:
American Journal of Gastroenterology. 116:855-861
Publikováno v:
Translational Gastroenterology and Hepatology. 8:8-8
Autor:
Kristopher P. Croome, Raouf E. Nakhleh, C. Burcin Taner, Sarah Croome, David Livingston, Peter A. Senada, David D. Lee, Maria L. Yataco
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyReferences. 25(10)
It has been suggested that microsteatosis does not negatively impact graft survival following liver transplantation (LT). The present study represents the largest series on donor livers with significant microsteatosis and investigates the impact of m
Publikováno v:
Gastroenterology. 160:S-785
Autor:
Maria L. Yataco, Amanda Chaney
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 25(7)
The evolving role of nurse practitioners (NPs) and physician assistants (PAs) in the United States continues to progress. NP and PA responsibilities have expanded from primary care practices to medical and surgical specialties. They provide acute car
Autor:
Johannes Bargehr, C.B. Taner, J. Aranda-Michel, Maria L. Yataco, Tushar Patel, Jorge F. Trejo-Gutiérrez, Surakit Pungpapong, Barry G. Rosser
Publikováno v:
Transplantation Proceedings. 45:2302-2306
In this study we described survival and incidence of perioperative and postoperative complications in liver transplant recipients with known atrial fibrillation. A total number of 717 patients underwent liver transplantation between January 2005 and
Autor:
Jennifer L. Murphy, Bashar Aqel, Ludi Koning, Barry G. Rosser, Andrew P. Keaveny, Surakit Pungpapong, Hugo E. Vargas, Kristen Ryland, Michael Charlton, Tanisha M. Henry, Maria L. Yataco, Raj Satyanarayana
Publikováno v:
Liver Transplantation. 19:690-700
The safety, efficacy, and effect on immunosuppression levels of telaprevir (TVR) or boceprevir (BOC) in combination with peginterferon (PEG-IFN) and ribavirin (RBV) in recipients of liver transplantation (LT) with hepatitis C virus (HCV) genotype 1 h
Autor:
Tushar Patel, Andrew P. Keaveny, C. Burcin Taner, Maria L. Yataco, Waseem David, Alissa Cowell
Publikováno v:
Annals of Hepatology, Vol 15, Iss 3, Pp 356-362 (2016)
While liver transplantation is the definitive therapy for end stage liver disease, it remains a major procedure, with many potential complications. Hospital readmissions after the initial hospitalization for liver transplantation can be associated wi
Publikováno v:
Clinical Liver Disease. 3:90-92
Autor:
Maria L. Yataco, Murli Krishna, Hugo Bonatti, Andrew P. Keaveny, Raj Satyanarayana, Winston R. Hewitt, Hani P. Grewal, Darin D. Willingham, Victor I. Machicao, Justin H. Nguyen, Jaime Aranda-Michel, Rolland C. Dickson, Barry G. Rosser, Christopher B. Hughes, Denise M. Harnois, Marwan Ghabril
Publikováno v:
Liver Transplantation. 13:1717-1727
Infection with hepatitis C virus (HCV) is the leading cause of liver transplantation (LT), while liver retransplantation (RT) for HCV is controversial as a result of concerns over poor outcomes. We sought to compare patient and graft survival after R